Key facts
- This page summarizes Robert F. Bartlett's Form 4 filing for PURE BIOSCIENCE, INC. (PURE).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 22 Aug 2024, 17:58.
Robert F. Bartlett - 20 Aug 2024 Form 4 Insider Report for PURE BIOSCIENCE, INC. (PURE)
- Reporting relationship
- CEO and President, Director
- Issuer ticker
- PURE
- Reported as of
- 20 Aug 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 22 Aug 2024, 17:58:36 UTC
- Prior SEC filing
- 03 Aug 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Robert Bartlett
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Robert F. Bartlett filed Form 4 for PURE BIOSCIENCE, INC. (PURE) on 22 Aug 2024.
Change
- Previous filing in this sequence was filed on 03 Aug 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
PURE
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +155,000
- Change %
- Price
- $0.000000
- Shares after
- 155,000
- Date
- 20 Aug 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 155,000
- Exercise price
- $0.0700
- Footnotes
- F1
PURE
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +500,000
- Change %
- Price
- $0.000000
- Shares after
- 500,000
- Date
- 20 Aug 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 500,000
- Exercise price
- $0.0700
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The option shares shall vest and become exercisable in four equal installments on November 20, 2024, February 20, 2025, May 20, 2025, and August 20, 2025.
Footnote F2
The option shares are fully vested as of the date of grant.